Previse is a groundbreaking startup based in Baltimore, Maryland, with a vision to save lives through the prediction and earlier detection of cancer, starting with esophageal cancer. The biotechnology research company has recently raised $3 million in seed funding from investors, including Gaingels, TEDCO, Riptide Ventures, and Wexford Science & Technology. The founder, Daniel Lunz, has developed a precision medicine solution called EsopredictTM, which offers personalized prognostic information to help gastroenterologists identify patients with Barrett's esophagus that are likely to progress to high-grade dysplasia or esophageal cancer. 

Built upon a foundation of proprietary epigenetic biomarkers and strong data science, EsopredictTM provides timely insights to patients and their healthcare providers about future risks of cancer progression. Previse aims to empower patients and healthcare providers with information to make informed decisions about surveillance and treatment for Barrett's esophagus, a precancerous condition. As a licensed healthcare provider, you can explore how EsopredictTM and EsoscoreTM reports can be used to support your patients in understanding their future risk of progression and the steps they can take to treat their condition. If you're looking for molecular testing for Barrett's esophagus surveillance and treatment decisions, EsopredictTM is the perfect solution.